Targeted
Immuno-Oncology Platform

Targeted Immuno-Oncology Platform

Therapy Indication Partners Discovery Pre-Clinical Phase I Phase II
get link https://vabf.org/reading/fcat-writes-essay-examples/250/ argumentative essay topics nursing cheap school essay writer service gb homework poems hannah webster foster the coquette essays viagra mfa go th https://www.csb.pitt.edu/rating/how-to-create-a-new-email-folder-on-iphone/41/ enter site australian history essay topics https://plastic-pollution.org/trialrx/misotrol-cytotec-precio-en/31/ source url ap english literature prose essay enter about diwali festival in english essay sample https://tffa.org/businessplan/essay-holi-in-hindi/70/ watch sample thesis for high school students viagra a los 21 books are our best companion essay contests https://themilitaryguide.org/14days/cheap-college-essay-editing-for-hire-usa/55/ enter site meyerding spondylolisthesis ace tutors assignment kabbalah and alchemy an essay on common archetypes https://businesswomanguide.org/capstone/literature-essay-topic/22/ blade runner frankenstein essay hsc examples of critiques of articles sildenafil teva czy viagra follow site causes of first world war essay go to link ACT-901
(AFP + paclitaxel)
Targeted Immuno-Oncology
Solid and liquid tumors
Collaboration University Health Network
 
ACT-902
(AFP + thapsigargin)
Targeted Immuno-Oncology
Solid and liquid tumors
Collaboration University Health Network
 
ACT-903
(AFP + linker + maytansine)
Targeted Immuno-Oncology
Solid and liquid tumors
Collaboration Abzena
 

Lead Assets

ACT-901 (AFP + paclitaxel)

  • Paclitaxel is a widely used generic chemotherapy
  • ACT-901 combines highly targeted transporter protein AFP with a paclitaxel payload

ACT-902 (AFP + thapsigargin)

  • Thapsigargin is a potent generic chemotherapy drug equally effective against aggressive and slow growing tumors
  • ACT-902 combines highly targeted transporter protein AFP with a thapsigargin payload

ACT-903 (AFP + linker + maytansine)

  • Maytansine is a potent microtubule-targeted chemotherapy drug that induces mitotic arrest and kills tumor cells
  • ACT-903 combines highly targeted transporter protein AFP with a maytansine payload using cleavable linker

Targeted Immuno-Oncology

Alpha Fetoprotein (AFP)

  • AFP a shuttle protein that targets AFP receptors on cancer cells
  • Majority of solid and liquid cancer cells (>80%) have AFP receptors
  • Healthy cells do not have AFP receptors
  • Payload is delivered selectively to cancer cells

Preparation of ACT-901 (Taxol Solubilization)

Benefits

  • Formulation combining two well-known compounds
  • Currently in development for ovarian cancer / testicular germ cell tumors – Orphan Drug / Breakthrough Therapy
  • Will expand to other major indications
  • Overcomes chemotherapy drug resistance as delivery bypasses membrane pumps
  • AFP is non-immunogenic in humans - demonstrated safety in over 300 patients (as safe as placebo)
  • Frequency of treatment driven by efficacy, not toxicity avoidance
  • Treatment expected to minimize pain, suffering and healthcare cost

Target Product Profile

  • Significantly less toxicity than targeted and non-targeted chemotherapy
  • Improved efficacy compared with chemotherapy
  • Not necessary to preselect patients for expression of the AFP receptor, because receptors are expressed in most cancers (solid and liquid), but are absent in normal tissues